Archive · 25 May 2025
India Launches PLI Scheme to Boost Pharma Manufacturing
The Indian government is offering money to drug companies that make certain medicines in India.
This program aims to help make more of these medicines inside the country instead of buying them from other places.
This PLI scheme includes 11 medicines, like those used to treat infections.
Companies have until June 14th to ask for this money.
This is part of a larger plan to boost manufacturing, create jobs, and increase exports.
The government previously launched similar schemes for other industries, with billions of dollars invested so far.
The Department of Pharmaceuticals is inviting applications for a PLI scheme.
The scheme targets 11 pharmaceutical products, including Neomycin and Ciprofloxacin.
June 14 is the deadline for manufacturers to apply.
The scheme is part of a broader government initiative to boost domestic manufacturing and exports.
The PLI scheme follows similar ones launched for other sectors four years ago.
- Who
- The Centre’s Department of Pharmaceuticals and drugmakers
- What
- A production-linked incentive (PLI) scheme for 11 pharmaceutical products to encourage new manufacturing capacities.
- When
- Applications due by June 14. The scheme was rolled out in May 2025.
- Where
- India
- Why
- To encourage domestic manufacturing of critical key starting materials, drug intermediates and active pharmaceutical ingredients and boost production, generate jobs and boost exports.
- Application Deadline
- June 14
- Eligible Products
- 11
- Incentive Tenure
- Up to FY28 (chemical synthesis), FY29 (fermentation-based)
- Investment in 14 sectors PLI schemes (by Nov 2024)
- $18.72 billion
- Incentives disbursed for 10 sectors
- ₹14,020 crore
- KSMs, DIs and APIs covered under the scheme
- 41 products